乌司他丁联合胸腺法新注射液治疗脓毒症的临床效果及对C反应蛋白、降钙素原的影响

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of Ulinastatin combined with Thymus New Injection in the treatment of sepsis and the effects on C reactive protein (CRP)and procalcitonin (PCT).Methods From July 2015 to July 2016,a total of 70 patients with sepsis were selected as objects.They were randomly divided into experimental group and control group with 35 cases in each group.The control group was treated with Ulinastatin and the experimental group was treated with Ulinastatin combined with Thymus New Injection.The levels of acute physiology and chronic health scoreⅡ(APACHEⅡ),CRP,PCT and adverse reactions were compared.Results After treatment,scores of APACHEⅡin both groups were significantly lower than those before treament,and the score of APACHEⅡof the experimental group was lower than that of the control group,the differences were statistically significant(P<0.05).After treatment,the levels of CRP and PCT in two groups were significantly lower than before treament,and the levels of CRP and PCT of the experimental group were significantly lower than those of the control group,the differences were statistically significant(P<0.05).One case in the experimental group developed adverse reactions during the course of treatment,and two cases in the control group,the adverse reaction condition of patients disappeared after adjustment.There were no adverse reactions that seriously affected the treatment in both groups.ConclusionUlinastatin combined with Thymus New Injection is effective in the treatment of patients with sepsis and can significantly improve the levels of CRP and PCT of patients.

Key words： Ulinastatin Thymus New Injection Sepsis Clinical effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Han-cong
	DENG Tao
	LI Jun-ling

Cite this article:

WU Han-cong,DENG Tao,LI Jun-ling. Clinical effect of Ulinastatin combined with Thymus New Injection in the treatment of sepsis and the effects on C reactive protein and procalcitonin[J]. 中国当代医药, 2018, 25(20): 125-127.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I20/125

[1]	李立为，刘霖，刘明蓉，等.参附注射液联合去甲肾上腺素治疗脓毒症休克大鼠与其对血红蛋白清道夫受体影响的研究[J].中华医院感染学杂志，2016，26（4）：763-765.
[2]	陈素敏，侯艳玲.参芪扶正注射液治疗小儿脓毒症的临床疗效分析[J].中国生化药物杂志，2015，35（4）：135-137.
[3]	季娟娟，孙耕耘.降钙素原和常用炎症指标在脓毒症诊断及预后中的价值[J].中华肺部疾病杂志（电子版），2015，8（4）：416-420.
[4]	Halim B，Zlem T，Melek，et al.Diagnostic and prognostic value of procalcitonin and sTREM-1 levels in sepsis[J].Turk J Med Sci，2015，45（3）：578-586.
[5]	Carr JA.Procalcitonin-guided antibiotic therapy for septic patients in the surgical intensive care unit[J].J Intensive Care Med，2015，3（1）：36-41．
[6]	师灵灵，韩艳秋，任慧娟，等.脓毒症的病理生理机制研究进展[J].中华医院感染学杂志，2016，26（8）：1914-1916.
[7]	肖为.脓毒症治疗的现状与新进展[J].医学综述，2014，20（8）：1425-1429.
[8]	龚天美，张咏梅，汪磊，等.血清降钙素原、C反应蛋白及血小板检测对脓毒症诊断及预后判断的临床意义[J].国际检验医学杂志，2017，38（7）：999-1001.
[9]	段君.乌司他丁对脓毒症患儿 TNF-α、IL-6、IL-10及肾功能的影响[J].中国实用医刊，2015，42（8）：115-116.
[10]	孙小聪，邵义明，黄河，等.乌司他丁对脓毒症急性肾损伤肾功能的保护作用[J].中华实验外科杂志，2015，32（4）：910-912.
[11]	黄增相，陶骅，徐雯，等.乌司他丁对严重脓毒症致急性呼吸窘迫综合征患者血浆C反应蛋白、降钙素原及乳酸水平的影响[J].实用医学杂志，2015，31（10）：1692-1694.
[12]	陈瑞娟，关小容.乌司他丁辅助治疗重症脓毒血症的疗效及对细胞因子的影响[J].实用临床医药杂志，2015，19（11）：130-132.
[13]	叶文，范骁钦，张中明，等.乌司他丁治疗脓毒症的疗效及对动脉血乳酸水平的影响[J].中国实用医刊，2015，42（19）：103-104.
[14]	董宏艳，刘先华，周智勇，等.降钙素原和APACHEⅡ评分对老年脓毒症患者病情判断及预后评估的研究[J].实用老年医学，2015，29（6）：457-460.
[15]	何勤，樊省廉，李艳.监测血清降钙素原和血小板对肺炎合并脓毒症患儿的预测价值[J].中国临床医生杂志，2015，43（10）：73-75.
[16]	彭红艳，祝益民，张新萍.降钙素原联合心脏相关标志物评估脓毒症患儿病情意义[J].临床儿科杂志，2015，33（1）：23-27.
[17]	张娙，董静莲，王书亮.降钙素原与D-二聚体在评估急诊脓毒症患者病情及预后的研究[J].中华医院感染学杂志，2015，25（1）：11-13.
[18]	吕志良.血清白蛋白、前白蛋白水平联合PCIS评分变化对脓毒症患儿预后评估的指导价值[J].泰山医学院学报，2017，38（2）：163-164.
[19]	刘峰.乌司他丁治疗脓毒症的临床效果观察[J].河南医学研究，2017，26（1）：81-82.
[20]	张声，张卫星，罗华，等.脓毒症患者血清降钙素原和C反应蛋白水平检测的临床价值[J].现代医学，2015，43（3）：303-306.